Kaunitz, A. M., Bitner, D., Constantine, G. D., Bernick, B., Graham, S., & Mirkin, S. (2020). 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial. Menopause.
シカゴスタイル引用形Kaunitz, Andrew M., Diana Bitner, Ginger D. Constantine, Brian Bernick, Shelli Graham, , Sebastian Mirkin. "17β-estradiol/progesterone in a Single, Oral, Softgel Capsule (TX-001HR) Significantly Increased the Number of Vasomotor Symptom-free Days in the REPLENISH Trial." Menopause 2020.
MLA引用形式Kaunitz, Andrew M., et al. "17β-estradiol/progesterone in a Single, Oral, Softgel Capsule (TX-001HR) Significantly Increased the Number of Vasomotor Symptom-free Days in the REPLENISH Trial." Menopause 2020.